Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science
Translational Behavioral Medicine October 17, 2024 Danielle R Adams, Heidi Allen, Ginger E Nicol et al. 7 citations
Psychedelic-assisted psychotherapy (PAT) shows promise for treating PTSD, depression, and substance use disorders, with potential FDA approval of psilocybin-assisted therapy for depression by 2026. This commentary calls for implementation scientists to collaborate with PAT researchers and practitioners to bring these treatments into routine practice, especially in safety-net settings like Federally Qualified Health Centers and Veterans Affairs health systems that serve historically marginalized populations. Using the RE-AIM Framework, the authors outline how implementation science can contribute tools, methodologies, and approaches to ensure PAT is safe, effective, and accessible for underserved communities.